Tubular Endogenous Erythropoietin Protects Renal Function against Ischemic Reperfusion Injury

Area of Science:

• Nephrology
• Renal Physiology
• Pharmacology

Background:

• Exogenous erythropoiesis-stimulating agents lack renoprotective effects in large-scale studies.
• Kidney ischemic reperfusion injury (IRI) poses a significant threat to renal function.
• Understanding endogenous erythropoietin (Epo) roles in renal protection is crucial.

Purpose of the Study:

• To investigate the renoprotective effects of endogenous Epo stimulated by a prolyl hydroxylase domain (PHD) inhibitor, Roxadustat (ROX).
• To differentiate the impact of tubular versus interstitial Epo production on kidney function following IRI.

Main Methods:

• Utilized a rodent model of kidney ischemic reperfusion injury (IRI).
• Administered Roxadustat (ROX) at varying pretreatment times (4h vs. 24-72h) before inducing IRI.
• Assessed renal function and measured Epo production in interstitial cells and renal tubules via immunohistochemistry.

Main Results:

• Short-term ROX (4h) or hypoxia did not improve renal function and increased interstitial Epo production, mimicking exogenous Epo effects.
• Long-term ROX pretreatment (24-72h) significantly improved renal function post-IRI.
• Long-term ROX induced Epo production in proximal and distal tubules, correlating with renoprotection.

Conclusions:

• Stimulation of tubular endogenous Epo production by prolonged ROX treatment confers renoprotection in kidney IRI.
• Peritubular Epo production induced by hypoxia or short-term ROX does not offer renoprotective benefits.
• Targeting tubular Epo production represents a potential therapeutic strategy for kidney injury.